ONCOMAO: Development of new cancer therapies based on MAO-A inhibition
Iteria Biopharma is part of the Public-Private Partnership project CPP2024-011416 funded by the Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación / 10.13039/501100011033 / FEDER / UE.
Development of new cancer therapies based on MAO-A inhibition
Iteria Biopharma has been funded by the Center for Technological Development and Innovation E.P.E. (CDTI), within the NEOTEC program (SNEO-20251130). This project has been supported by the Ministry of Science, Innovation and Universities.
Iteria Biopharma has been funded by Inveready. Inveready is a leading asset management firm. Founded in 2008, it has grown to become one of the most active investment firms in the small and mid-cap segment in Spain, managing more than €2.5 billion in assets.
Iteria Biopharma has been funded by Xesgalicia. Xesgalicia is the venture capital management company of the Xunta de Galicia, whose objective is to support the Galician business ecosystem through four differentiated investment vehicles, tailored to different project types and stages of the business lifecycle — from early-stage business initiatives to the implementation of large industrial projects or the growth and consolidation of established companies with a proven track record.
